Phuturdex › Diseases › Burkitt lymphoma
Drugs in development · updated 30 October 2026
Burkitt lymphoma: drugs in development
As of 30 October 2026 there are 117 active clinical trials (recruiting or ongoing, phases I–III) on 113 drugs for Burkitt lymphoma. 34 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| IgPro20 | III | 1 | NCT07648264 |
| MK-1045 | II–III | 1 | NCT07570173 |
| CD19 | I–II | 4 | NCT05442515 |
| CD22 | I–II | 3 | NCT07575971 |
| CLLS52 | I–II | 1 | NCT04150497 |
| IMT-009 | I–II | 1 | NCT05565417 |
| MB-CART19.1 | I–II | 1 | NCT07890025 |
| MGTA 456 | II | 1 | NCT03674411 |
| PidnarulexCX-5461 | I–II | 1 | NCT07069699 |
| Sepantronium Bromide | II | 1 | NCT05263583 |
| SurovatamigAZD0486 | I–II | 1 | NCT06137118 |
| UCART22 | I–II | 1 | NCT04150497 |
| Varlilumab | II | 1 | NCT03038672 |
| VNX-101 | I–II | 1 | NCT06533579 |
| YK012 | I–II | 1 | NCT06580301 |
| Zilovertamab vedotin | I–II | 1 | NCT06395103 |
| B019 | I | 1 | NCT06927466 |
| CD19-CD34 | I | 1 | NCT04214886 |
| CD20 | I | 1 | NCT05418088 |
| CLIC-2201 | I | 1 | NCT06208735 |
| DuoCAR20.19.22-D95 | I | 1 | NCT06879340 |
| GC019F | I | 1 | NCT04595162 |
| KITE-753 | I | 1 | NCT07674823 |
| NKTR-255 | I | 1 | NCT03233854 |
| NKX019 | I | 1 | NCT05020678 |
| PIT565 | I | 1 | NCT05397496 |
| SGR-1505 | I | 1 | NCT05544019 |
| VIP943 | I | 1 | NCT06034275 |
| GI001 | Early I | 1 | NCT07862010 |
| GT801 | Early I | 1 | NCT07205315 |
| JY231 | Early I | 1 | NCT06514768 |
| QH10304-BAL-01 | Early I | 1 | NCT06696833 |
| SNC116 | Early I | 1 | NCT07830238 |
| SYNCAR-100 | Early I | 1 | NCT07429461 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CyclophosphamideCyclophosphamid, Cytoxan | II–III | 47 | NCT07724457 |
| BlinatumomabBlincyto® | II–III | 30 | NCT07570173 |
| VincristineVincristin, Oncovin [vincristine] | II–III | 25 | NCT07724457 |
| FludarabineFludara, FLUDARABIN | III | 22 | NCT07223021 |
| MethotrexateJylamvo®, Reditrex® | II–III | 22 | NCT07724457 |
| CytarabineAra-C, Cytosine Arabinoside | II–III | 21 | NCT07724457 |
| PrednisonePredinisone, Cortancyl | II–III | 21 | NCT07724457 |
| DexamethasoneDexametasone, Dextenza | II–III | 19 | NCT07570173 |
| DoxorubicinAdriamycin, Doxorubincin | II–III | 16 | NCT07724457 |
| Mercaptopurine6-Mercaptopurine, Mecaptopurine | III | 16 | NCT02101853 |
| EtoposideAvopef®, Etopophos Preservative Free® | II–III | 15 | NCT07724457 |
| Inotuzumab OzogamicinBesponsa® | III | 14 | NCT07476729 |
| RituximabRuxience, Rituxan | II–III | 14 | NCT07724457 |
| VenetoclaxVentoclax, Venclexta® | II–III | 13 | NCT06764238 |
| PegaspargasePegylated-asparaginase, PEG asparaginase | III | 11 | NCT02101853 |
Sorted by most advanced phase and number of active trials. Showing 15 of 79 drugs.
All 113 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
- Infection 71 drugs
- Immune System Diseases 54 drugs
- Lymphoproliferative disorders 51 drugs
- Immunoproliferative disorder 16 drugs
- DNA virus infectious disease 6 drugs
- Virus Diseases 26 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D002051 “Burkitt Lymphoma”. Prevalence: Orphanet.